The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery

Red Blood Cell Transfusion Clinical Trial

— TheRAPy  

Official title:

The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery (TheRAPy): a Multiple Period Vanguard Cluster Crossover Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06230198
• Other study ID #: TheRAPy
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2024
• Est. completion date: March 2025

Study information

• Verified date: January 2024
• Source: Population Health Research Institute
• Contact: TheRAPy Study Coordinator
• Phone: 9055212100
• Email: therapy[@]phri.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.

Description:

About 50% of patients undergoing cardiac surgery require red blood cell (RBC) transfusion. Given the limited blood supply and harms of transfusion, evidence-based blood conservation strategies are a priority. There is one such simple conservation technique called Retrograde autologous priming (RAP), in which the patient's own blood, rather than crystalloid fluid, is used to prime the heart-lung machine. Ultimately, it minimizes the loss of RBCs during surgery. Despite evidence of RAP reducing incidence of RBC transfusions by 40% and RBC units transfused by 38% in small randomized trials, it is not routinely used due to the uncertainty about overall benefit and potential harms. Routine RAP may be beneficial, but this needs to be confirmed in a large pragmatic randomized trial. Therefore, the goal of this vanguard trial is to assess the feasibility of a full-scale multi-centre randomized cluster crossover trial to determine whether an institutional policy of routine RAP reduces the number of RBC units transfused up to 72 hours after cardiac surgery compared to crystalloid priming. This will include 4 sites that will test the two policies in an alternating sequence during 12 periods of 4 weeks, with an expected volume of 4500 cardiac surgery patients. If the adherence to both polices is >=90%, a full trial will be conducted. The findings of this study have the potential to improve the outcomes of tens of thousands of patients around the world and will provide the basis for cardiac practice guidelines.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 4500
• Est. completion date: March 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years to 110 Years

Eligibility

Inclusion Criteria:

• Hospitals completing >200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.
• All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.

Exclusion Criteria:

• 1) Complete <=200 cardiac surgical cases. 2) <95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.

Related Conditions & MeSH terms

• Red Blood Cell Transfusion

Intervention

Procedure:
• retrograde autologous priming (RAP)
whether an institutional policy of routine use of retrograde autologous priming (RAP) reduces red blood cell (RBC) transfusion compared to crystalloid priming up to 72 hours after cardiac surgery

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Population Health Research Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of implementing a full-scale randomized cluster crossover trial where feasibility is defined as adherence >90% to both institutional policies applied in random sequence	The primary objective is to assess the feasibility of a full-scale randomized cluster crossover trial to determine whether an institutional policy of routine use of retrograde autologous priming (RAP) reduces red blood cell (RBC) transfusion compared to crystalloid priming up to 72 hours after cardiac surgery. We will define feasibility as adherence >90% to both institutional policies applied in random sequence.	6 months
Secondary	Critical Parameters	to collect data about critical parameters that affect the design and implementation of the full-scale trial	6 months